Xenon reports FY2021 net loss $78.9M; XEN1101 Phase 3 expected H2 2022

Xenon Pharmaceuticals Inc.

2022-FY EPS reported -$1.77 revenue$18,437,000

Net loss $78.9M vs $28.8M in 2020; revenue $18.4M vs $32.2M.
Cash $551.8M (Dec 31, 2021) vs $177.0M; expects funding into at least 2024.
XEN1101 Phase 2b met primary endpoint; end-of-Phase 2 FDA meeting Q2 2022; Phase 3 start H2 2022.
XEN496 Phase 3 EPIK trial for KCNQ2-DEE enrolling; completion expected H1 2023.
Partner Neurocrine Phase 2 for NBI-921352 ongoing; Pacira Phase 1b for PCRX301 data expected Q2 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.